knowledge -WSS

knowledge

author：leisure time 2025-09-30 18:21:13 - browse：99

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

WSS

The CDC's new social media misinformation war

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Massive project maps cells in human brain in unprecedented detail

Readout LOUD: Venture capital, Gilead, and more M&A

STAT Readout Newsletter: Today in biotech, life science news

Wellcome Trust names Røttingen as its new CEO

focus

knowledge

hotspot

Walensky prepares to leave CDC — and Congress — behind

Adopting new red light myopia treatments may be short

Cancer drug shortages should be causing more outrage

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Psychedelics group wrestles with new pharma identity

The CDC's new social media misinformation war

State Dept. review finds Biden bears some blame for Afghanistan failures

Wellcome Trust names Røttingen as its new CEO

Sports medicine is finally prioritizing gender equality

European regulators consider appeal over Amylyx ALS drug

focus

Peter Marks talks Operation Warp Speed for Rare Diseases

Wellcome Trust names Røttingen as its new CEO

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Nick Jonas talks about managing diabetes along with his career

What’s missing from the debate over nursing home staff minimums

Wellcome Trust names Røttingen as its new CEO

knowledge

focus

focus

entertainment